Phase 3 multi-center double-blind randomized crossover study of the efficacy safety and tolerability of fixed combination torcetrapib (Cp-529 414)/atorvastatin, compared with atorvastatin therapy alone, and fenofibrate alone, in subjects with Fredrickson type III hyperlipoproteinemia (familial dysbetalipoproteinemia).

Trial Profile

Phase 3 multi-center double-blind randomized crossover study of the efficacy safety and tolerability of fixed combination torcetrapib (Cp-529 414)/atorvastatin, compared with atorvastatin therapy alone, and fenofibrate alone, in subjects with Fredrickson type III hyperlipoproteinemia (familial dysbetalipoproteinemia).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Atorvastatin; Fenofibrate; Torcetrapib/atorvastatin
  • Indications Hyperlipoproteinaemia type III
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2012 Actual patient number is 41 according to ClinicalTrials.gov.
    • 05 Dec 2006 Status change
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top